Pharma Mar (OTCMKTS:PHMMF – Get Free Report) is projected to issue its results before the market opens on Monday, March 2nd. Analysts expect the company to announce earnings of $2.78 per share and revenue of $84.6250 million for the quarter.
Pharma Mar Price Performance
OTCMKTS PHMMF opened at $88.72 on Monday. Pharma Mar has a fifty-two week low of $80.91 and a fifty-two week high of $110.40. The stock’s 50-day moving average is $88.45 and its two-hundred day moving average is $92.24. The company has a debt-to-equity ratio of 0.19, a quick ratio of 2.25 and a current ratio of 2.84.
About Pharma Mar
PharmaMar is a Spain-based biopharmaceutical company that specializes in the discovery and development of novel oncology therapies derived from marine organisms. Founded in 1986 as part of Grupo Zeltia, the company has pioneered the use of compounds extracted from deep-sea organisms to create synthetic analogs aimed at treating various forms of cancer. Its core expertise lies in marine biotechnology, medicinal chemistry and oncology-focused clinical development.
The company’s flagship product is Yondelis (trabectedin), an antitumor agent approved in the European Union for the treatment of soft tissue sarcoma and relapsed platinum-sensitive ovarian cancer.
Featured Articles
- Five stocks we like better than Pharma Mar
- The gold chart Wall Street is terrified of…
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
- This $15 Stock Could Go Down as the #1 Stock of 2026
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
Receive News & Ratings for Pharma Mar Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharma Mar and related companies with MarketBeat.com's FREE daily email newsletter.
